Report Overview

The Diabetes drugs market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Diabetes is the most common glycogen metabolism disorder in Kenya. The World Health Organization (WHO) estimates that the prevalence of diabetes in Kenya at 3.3% and predicts a rise to 4.5% by 2025. However, two-thirds of diabetics may be undiagnosed. Higher rates of diabetics are found in urban areas. Urbanisation and adoption of Western lifestyles have led many Kenyans towards risk for developing DM. Kenya has seen increase in abdominal obesity, poor dietary habits, excess alcohol consumption, smoking and physical inactivity. Foot ulcers are seen frequently at many tertiary clinics in Kenya and are associated with poor glycaemic control, infection, hypertension and dyslipidaemia.



Market Drivers

The market is majorly driven by the increasing prevalence of Diabetes in Kenya. About 1% of deaths in Kenya were directly attributable to diabetes in 2012.

The Base of the Pyramid (BoP) project is a publicprivate partnership initiated by Novo Nordisk that aims to facilitate access to diabetes care for people at the base of the economic pyramid in low- and middle-income countries (LMICs). In Kenya, the BoP, through a partnership model, aims to strengthen five pillars of diabetes care: increased awareness of diabetes; early diagnosis of diabetes; access to quality care by trained professionals; stable and affordable insulin supply; and improved self-management through patient education.

Increasing initiatives by Government of Kenya by Implementation of National Diabetes Strategy in 2015 has led to establishment of hospital diabetes clinics in nine provinces of the country. A Diabetes Education Programme has also been implemented for healthcare staff.

Overall, Rise in the prevalence of diabetes, Increased initiatives by private pharmaceutical companies and partnerships with Government and increase in the healthcare expenditure are fuelling growth in diabetes treatment market in Kenya.

Diabetes requires long-term follow up, with uninterrupted access to medication and specialist care. Low levels of public awareness, high cost of Insulin, non-adherence to treatment, poor behaviours towards diabetes and unwillingness to adopt healthier lifestyles are hindering growth of metabolic disorders therapeutics market.